Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraSphere in Unresectable Hepatocellular Carcinoma
NCT02072356Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2010
- Primary completion
- Jun 2021
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of yttrium-90 in hepatocellular carcinoma (HCC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Objective Response Rate at 2 years and Overall Survival at 2 years. Started Oct 2010; status: completed.
02
Drugs
yttrium-90
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02072356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072356.